 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...6061626364656667686970...132133» |
- | everolimus / Generic mfg.
Journal: The Cone Flare Crush Modified-T (CFCT) stenting technique for coronary artery bifurcation lesions. (Pubmed Central) - Oct 7, 2020
From April 2018 until March 2019, 20 consecutive patients underwent bifurcation PCI using the CFCT technique with a Pt-Cr everolimus drug-eluting stent with a bioresorbable polymer...Expanded and randomized datasets with longer term follow-up are required to further explore confirm this feasibility data. (ANZCTR ID: ACTRN12618001145291).
- |||| everolimus / Generic mfg., VS-6766 / Verastem
Ro5126766 (VS-6766) /Everolimus UK trial is exploring BRAF cohort, among others. More US studies are needed. https://t.co/asJrfhORBL (Twitter) - Oct 4, 2020
- everolimus / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Cost-effectiveness of Nivolumab in Patients with Pre-treated Advanced Renal Cell Carcinoma (aRCC) in the United States- Impact of -5 Years of Follow-up Data from Checkmate 025 () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1685;
P3
CONCLUSIONS : The initial DBL conservatively underestimated the incremental lifetime survival benefit for nivolumab versus everolimus when compared with estimates using the latest DBL from CheckMate 025. Higher total incremental costs observed with longer follow-up were offset by increased LY and QALY gains between DBLs.
- everolimus / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] A Study to Assess the Impact of Incorporating the ‘Probability of Being in Response Function’ into an Economic Model for Nivolumab in Advanced Renal-Cell Carcinoma () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1248;
CONCLUSIONS : The PSM augmented with PBRF provided a more detailed assessment of QALYs gained in the PF state for nivolumab and everolimus than the 3-state PSM. Model developers should consider this approach when there are marked differences in the response profiles of competing interventions.
- everolimus / Generic mfg.
[VIRTUAL] Lutetium (177LU) Oxodotreotide Versus Standard of Care in Adult Patients with Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS)- A Cost-Consequences Analysis from an Italian Hospital Perspective () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_395;
Model developers should consider this approach when there are marked differences in the response profiles of competing interventions. From an Italian NHS perspective, in both panNET and giNET adult patients, lutetium (177Lu) oxodotreotide provides more PFS months gained, highly compensating the drug acquisition and administration costs, as revealed by the lower costs/PFS ratio compared with the other therapeutic options.
- everolimus / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] The Comparative Pharmacoeconomic Analysis of Using Cabozantinib As Second-LINE Therapy for Adult Patients with Metastatic Renal Cell Carcinoma in Russia () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_319;
Efficacy analysis showed the highest rates of LYG (3.18) and QALY (1.87) for cabozanthinib compared with nivolumab (2.53 LYG and 1.6 QALY), axitinib and everolimus (2.21 LYG and 1.31 QALY)... Using cabozantinib as second-line therapy in mRCC in adult patients was effective and economically justified treatment option in Russia.
- everolimus / Generic mfg.
[VIRTUAL] The Outcomes-Based Risk-Sharing MODEL for Targeted Drugs Based on the Czech National Register of Reimbursed Health Services () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_45;
In sunitinib patients, the model when 90% length of treatment in clinical trial (9.9 months) separates responders and non-responders, 57.2% patients treated with sunitinib would be reimbursed by manufacturer which made 23.6% of total cost of treatment (in 80% and 70% model: 52.7% and 47.4% patients which made 19.9% and 16.0% of costs). CONCLUSIONS : We proposed and tested feasible reimbursement model on national level data that closely align price and value of reimbursed product and reduces the risks associated with high-cost pharmaceuticals with uncertain real-world outcomes.
- || everolimus / Generic mfg.
RE: Dr. Yao's talk and the finding that mTOR mutations do not predict response to everolimus, what data might be needed to drive mechanistic computational models to explore that non-intuitive finding? @CureNETs @PamelaKunzMD @PoHienEar @marklewismd #NANETSgoesVirtual (Twitter) - Oct 3, 2020
- || Piqray (alpelisib) / Novartis, everolimus / Generic mfg.
Clinical, Review, Journal: Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. (Pubmed Central) - Oct 3, 2020
Based on the available efficacy and safety data, the "new" alpelisib may be burdened by higher incidence of severe adverse events, higher costs, and anticancer efficacy that is limited to PIK3CA-mutated tumors when compared to the "old" everolimus. Therefore, the everolimus-exemestane combination remains an effective and reasonably well-tolerated therapeutic option for HR+ HER2- mBC patients progressing after/on previous AI treatment, independently of PIK3CA mutational status.
- alisertib (MLN8237) / Takeda
[VIRTUAL] Randomized phaseII trial to evaluate alisertib alone or combined with fulvestrant for advanced, endocrine-resistant breast cancer (TBCRC 041) (Channel 2) - Oct 2, 2020 - Abstract #SABCS2020SABCS_1170;
More severe toxicities and treatment discontinuation were observed in pts receiving combination therapy. Correlative blood (CTC/cfDNA) and tissue (AURKA, ERα, and stemness biomarkers) studies are underway.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Aliqopa (copanlisib) / Bayer
[VIRTUAL] Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive metastatic breast cancer with PIK3CA mutation or PTEN mutation () - Oct 2, 2020 - Abstract #SABCS2020SABCS_1150;
In the phase III CLEOPATRA trial, while the combination of pertuzumab (P) plus trastuzumab (H) plus docetaxel (T) as compared with trastuzumab (H) plus docetaxel (T), significantly prolonged PFS (18.5 vs 12.4 months) for first-line treatment for HER2-positive (+ve) metastatic breast cancer (MBC), longer median PFS was observed in patients with wildtype versus mutated PIK3CA in both the control (13.8 v 8.6 months) and pertuzumab groups (21.8 v 12.5 months)...To have 82 evaluable patients with a 15% dropout rate, we would need to enroll 96 patients. A Wieand rule futility interim analysis will be conducted when half of the total of 54 required PFS events are observed.
- everolimus / Generic mfg., fulvestrant / Generic mfg.
[VIRTUAL] EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer () - Oct 2, 2020 - Abstract #SABCS2020SABCS_1098;
P1a/1b
Novel degraders and antagonists of ER are under evaluation, to overcome both ER mediated resistance and the bioavailability and dosing limitations of fulvestrant (fulv), the only approved SERD...Preclinically, LY3484356 monotherapy shows favorable efficacy and pharmacokinetic (PK) properties, including antitumor activity in ESR1 mutants, along with enhanced antitumor efficacy when combined with abemaciclib, everolimus, or alpelisib...Key Study endpoints: Recommended phase 2 dose determination; safety and tolerability assessment, PK evaluation, objective response rate and clinical benefit rate assessment per RECIST v1.1. Recruitment for the EMBER study is ongoing (NCT04188548).
- tamoxifen / Generic mfg., everolimus / Generic mfg., fulvestrant / Generic mfg.
[VIRTUAL] From clinical trials to clinical practice: Real-life outcome data of everolimus and exemestane in the treatment of patients with metastatic breast cancer (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_801;
Fulvestrant was given as a third line endocrine therapy in 54 (59.3%) patients...Conclusions : Despite enrolling sicker and heavier-pretreated patients, our real-life outcome data for both efficacy and safety of exemestane and everolimus matches those reported in major clinical trials. Such results should assure clinicians and should lead to wider utilization of this oral, chemotherapy-sparing regimen.
- everolimus / Generic mfg.
[VIRTUAL] Maintenance therapy with everolimus plus aromatase inhibitors vs aromatase inhibitors as after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Updated analyses of the phase III randomized MAIN-A trial (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_799;
No difference in OS was observed between the two arms (median 33.9 mos for EVE+AI vs 33.5 mos for AI, HR 0.97, 95% CI 0.59-1.61). Conclusions Maintenance EVE+AI did not significantly impact on the outcome of metastatic breast cancer patients deemed suitable for first line chemotherapy.
- Avastin (bevacizumab) / Roche
[VIRTUAL] First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_798;
In our registry, first-line chemotherapy for luminal MBC was significantly associated with an inferior PFS and OS compared to endocrine-based therapy. Because of the retrospective design of the study, biases influencing these results cannot be fully excluded, however, our data suggest that first-line chemotherapy should be avoided in luminal MBC.
- everolimus / Generic mfg.
[VIRTUAL] Efficacy of everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer in patients previously treated with CDK4/6 inhibitors (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_795;
Because of the retrospective design of the study, biases influencing these results cannot be fully excluded, however, our data suggest that first-line chemotherapy should be avoided in luminal MBC. Patients who received a prior CDK4/6 inhibitor had a lower median PFS benefit from EVE+EXE compared to those who did not.
- everolimus / Generic mfg., fulvestrant / Generic mfg.
[VIRTUAL] Single-centre retrospective study of treatment choices and outcomes of metastatic breast cancer post-progression on the CDK4/6 inhibitor palbobiclib (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_736;
In this real-world analysis, we found that palbociclib was most tolerated at 75 mg and most prescribed with an AI. After progression on CDKi, the tendency was to prescribe a chemotherapy-based subsequent line, mainly capecitabine.
- everolimus / Generic mfg.
[VIRTUAL] Adherence to and patient satisfaction with the combination therapy of exemestane and everolimus in postmenopausal women with HR+ HER2- advanced breast cancer: Results from the IPSOC-mamma study (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_619;
Many patients needed to interrupt the treatment due to side effects; treatment is perceived as intensive. Nevertheless, median PFS is 170 days, even when used late in the therapeutic journey of breast cancer patients.
- Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
[VIRTUAL] Identification of novel molecules that enhance neratinib efficacy in triple-negative breast cancer by high-throughput RNA interference (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_337;
In vivo experiments demonstrated that neratinib plus everolimus and neratinib plus trametinib combinations inhibited tumor growth in the SUM149 xenograft model for than single drug (neratinib, 42.3% growth inhibition; everolimus, 29.7%; trametinib, 47.1%; neratinib plus everolimus, 69.7%; neratinib plus trametinib, 77.7%; P < 0.0001). Conclusion : Combining neratinib with everolimus or with trametinib enhanced the antitumor effects of these drugs in TNBC regardless of PIK3CA mutation status, and clinical investigations evaluating these combination regimens for the treatment of TNBC are warranted.
- entinostat (SNDX-275) / Kyowa Hakko Kirin, Syndax Pharma
[VIRTUAL] E2112: randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. a trial of the ecog-acrin cancer research group (Channel 1) - Oct 2, 2020 - Abstract #SABCS2020SABCS_148;
P3
The combination of exemestane and entinostat did not improve survival in AI resistant advanced HR-positive, HER2-negative breast cancer. Pharmacodynamic analysis confirmed target inhibition in entinostat-treated patients.
- || everolimus / Generic mfg.
Clinical, Journal: S1Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study. (Pubmed Central) - Oct 2, 2020
These results suggest that de novo heart transplant patients randomized to everolimus and low-dose CNI followed by CNI-free therapy maintain significantly better long-term renal function as well as significantly reduced CAV, than patients randomized to standard CNI treatment. Increased BPAR in the everolimus group during year 1 did not impair long-term graft function.
- || Clinical, P2 data, Journal: Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: A multi-center, single arm, phase II study. (Pubmed Central) - Oct 2, 2020
Everolimus, letrozole and metformin resulted in 50% CB and 28% OR in women with recurrent EC. Progesterone receptor positive tumors may have better response; validation studies are needed.
- | everolimus / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
Retrospective data, Journal, Monotherapy, Real-World Evidence: A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data. (Pubmed Central) - Oct 2, 2020
Progesterone receptor positive tumors may have better response; validation studies are needed. Nivolumab was effective and well-tolerated in real-world Japanese mRCC patients.
- | everolimus / Generic mfg.
Trial completion date, Trial primary completion date: STARR: Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection (clinicaltrials.gov) - Oct 2, 2020
P=N/A, N=20, Not yet recruiting, Sponsor: Hospices Civils de Lyon
Nivolumab was effective and well-tolerated in real-world Japanese mRCC patients. Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: May 2022 --> Aug 2022
- | everolimus / Generic mfg., sirolimus / Generic mfg.
Journal: Effects of autophagy inducers on recombinant antibody production in insect cells. (Pubmed Central) - Oct 2, 2020
Unlike rapamycin, another autophagy inducer, FK506, was ineffective in insect cells. The addition of an appropriate autophagy inducer may be effective in increasing the productivity of recombinant proteins in insect cells.
- ||||| Avastin (bevacizumab) / Roche, everolimus / Generic mfg.
Clinical: In this phase 2 trial, the combination of everolimus + bevacizumab demonstrated robust activity in patients with papillary variant RCC, supporting this regimen as a standard first-line treatment option in these patients. @DrDarrenFeldman @sloan_kettering https://t.co/XLq1c7nF3u (Twitter) - Oct 1, 2020
- || Ibrance (palbociclib) / Pfizer, everolimus / Generic mfg., fulvestrant / Generic mfg.
Clinical, Journal: Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients. (Pubmed Central) - Oct 1, 2020
The addition of an appropriate autophagy inducer may be effective in increasing the productivity of recombinant proteins in insect cells. The fulvestrant and palbociclib combination exerts an appreciable effect on metastatic heavily pretreated patients with a tolerable toxicity profile.
- || everolimus / Generic mfg.
Clinical, Journal: A Case of Small Cell Carcinoma of the Bladder (Pubmed Central) - Oct 1, 2020
He underwent 9 courses of EP chemotherapy, and everolimus, finally, Amrubicin was administered. Amrubicin might be useful for small cell carcinoma of the bladder.
- |||||| everolimus / Generic mfg., exemestane / Generic mfg.
Clinical: Our abstract on efficacy of everolimus+exemestane after CDK4/6 inhibitors in metastatic breast cancer was accepted as a poster presentation @SABCSSanAntonio! #CleClinicCancer #bcsm Thank you all for the guidance! @HalleMooreMD @MeganKruseMD @jamecancerdoc @Montero_MD @gt_budd (Twitter) - Sep 30, 2020
- ||| everolimus / Generic mfg., erlotinib / Generic mfg.
Trial termination: RAD001 and Erlotinib in Patients With Neuroendocrine Tumors (clinicaltrials.gov) - Sep 28, 2020
P2, N=17, Terminated, Sponsor: University of California, San Francisco
Amrubicin might be useful for small cell carcinoma of the bladder. Completed --> Terminated; Low Accrual
- ||| Rituxan (rituximab) / Roche
Trial completion: Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma (clinicaltrials.gov) - Sep 28, 2020
P2, N=56, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Completed --> Terminated; Low Accrual Active, not recruiting --> Completed
- [VIRTUAL] Phase 2 trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): results by independent imaging review and subgroup analyses () - Sep 27, 2020 - Abstract #COSA2020COSA_279;
PEMBRO + axitinib is approved first-line for advanced RCC...No new safety signals were detected. Efficacy by investigator assessment irRECIST N=104 ORR, n/N (%) [95% CI] 57/104 (54.8) [44.7-64.6] Prior anti-PD-1/PD-L1 and anti-VEGF 40/68 (58.8) [46.2-70.6] Prior nivolumab + ipilimumab 18/38 (47.4) [31-64.2] PD-L1 status Positive 22/44 (50) [34.6-65.4] Negative 27/43 (62.8) [46.7-77] ORR(week 24), n (%) [95% CI] 53 (51) [41-60.9] DORa (95% CI) 12.2 (8.5-18.2) Time to responsea (range) 1.6 (1.2-13.7) PFSa (95% CI) 11.7 (9.4-17.7) OSa Not reached aMedian, months
- |||||| Avastin (bevacizumab) / Roche, everolimus / Generic mfg.
Clinical, Next-Generation Sequencing: Everolimus Plus Bevacizumab in 1L Rx of Patients With Papillary Variant mRCC: ⭕️6-month PFS 78% (in ARID1A 7/7 and FH 10/11 - NGS MSK-IMPACT) ⭕️ORR 35% ⭕️PFS 13.7 and OS 33.9 months @JournalCancer @OncoAlert @DrDarrenFeldman @motzermd @sloan_kettering https://t.co/zSBvT6jWQx (Twitter) - Sep 27, 2020
- | everolimus / Generic mfg.
Biomarker, Journal: Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment? (Pubmed Central) - Sep 27, 2020
pretherapeutic ASP of SSR positive lesions independently predicted PFS for treatment with everolimus in GEP-NET. ASP may supplement risk-benefit assessment before patient inclusion to treatment.
- | tacrolimus / Generic mfg., everolimus / Generic mfg.
Preclinical, Journal: Small-Molecule Immunosuppressive Drugs and Therapeutic Immunoglobulins Differentially Inhibit NK Cell Effector Functions in vitro. (Pubmed Central) - Sep 26, 2020
Proliferation was inhibited by methylprednisolone (MePRD), mycophenolic acid (MPA), and everolimus (EVE)...The most potent drug with an effect on all NK functions was MePRD. The fact that MePRD and IVIg significantly block NK cytotoxicity, especially ADCC, has major implications for AbMR as well as therapeutic strategies targeting cancer and immune cells with monoclonal antibodies.
- || everolimus / Generic mfg., Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Clinical, P2a data, Journal: A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. (Pubmed Central) - Sep 26, 2020
The fact that MePRD and IVIg significantly block NK cytotoxicity, especially ADCC, has major implications for AbMR as well as therapeutic strategies targeting cancer and immune cells with monoclonal antibodies. Despite this trial had to be terminated earlier due to low recruitment, the results match the other studies published so far with the mTOR inhibitor everolimus and SUN, which show a trend in favor of SUN for ORR and PFS.
- || Ibrance (palbociclib) / Pfizer, everolimus / Generic mfg.
Clinical, Journal, HEOR: Cost-effectiveness and safety of palbociclib and everolimus for treating advanced and recurrent breast cancer. (Pubmed Central) - Sep 25, 2020
In terms of discontinuation owing to adverse events (AEs), pneumonitis, thrombocytopenia, edema, fatigue, and neutropenia were experienced in the everolimus group. The cost-effectiveness of everolimus and palbociclib are equivalent, but since the prevalence of AEs is high in patients receiving everolimus, its AE management is important.
- || everolimus / Generic mfg.
Clinical, Review, Journal: Evidence-based protocol-led management of renal angiomyolipoma: A review of literature. (Pubmed Central) - Sep 25, 2020
Patients with TSC can be offered mammalian target of rapamycin inhibitors of which everolimus appears to cause the greatest shrinkage of tumors with an acceptable side-effect profile...High-risk tumors should be treated with SAE or surgery. Systemic treatments are the first-line of treatment for patients with TSC to preserve renal parenchyma.
- Avastin (bevacizumab) / Roche
[VIRTUAL] Real-world outcomes of non:clear cell renal cell carcinoma: Retrospective study from tertiary cancer center in India (Channel 2) - Sep 24, 2020 - Abstract #ESMOAsia2020ESMO_Asia_105;
51 (32%) patients were metastatic at presentation; 3 received supportive care alone due to poor performance status, 39.2% received sorafenib, sunitinib 27.4%, pazopanib 21.6% while bevacizumab erlotinib was given to 5.9% patients as first-line therapy...Only 21 (43.8%) could receive second-line therapy with everolimus being the most commonly used (38%)...Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- ||| rocapuldencel-T (CMN-001) / CoImmune, SCM Lifescience
Enrollment open, Trial initiation date, Metastases: Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Sep 24, 2020
P2b, N=120, Recruiting, Sponsor: CoImmune
Funding: Has not received any funding. Not yet recruiting --> Recruiting | Initiation date: Mar 2020 --> Jul 2020
- || everolimus / Generic mfg., clotrimazole / Generic mfg.
Clinical, PK/PD data, Journal: Clotrimazole troches can alter everolimus pharmacokinetics in post-transplant patients: A case report. (Pubmed Central) - Sep 23, 2020
Not yet recruiting --> Recruiting | Initiation date: Mar 2020 --> Jul 2020 No abstract available
- || everolimus / Generic mfg., Sutent (sunitinib) / Pfizer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Biomarker, Clinical, Clinical data, Journal, PD(L)-1 Biomarker, IO Biomarker: PD-L1 expression and clinical outcomes to cabozantinib, everolimus and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN. (Pubmed Central) - Sep 23, 2020
P2, P3
Higher PD-L1 expression results in worse clinical outcomes in mRCC treated with targeted therapy. Furthermore, PD-L1 expression is not predictive of response to cabozantinib therapy.
- Leustatin (cladribine) / J&J, Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] New drugs for low grade lymphoproliferative diseases (ATİLLA YALÇIN HALL) - Sep 23, 2020 - Abstract #EHOC2020EHOC_28;
Tazemetostat a novel EZH2 inhibitor recently received accelerated approval by FDA for patients with RR-FL and EZH2 gene mutations, following the results of a phase-II study...Immune check point inhibitors (Nivolumab, Pemprolizumab, Atezolizumab) are promising as third line treatment and beyond. Other agents under investigation include the inhibitor of nuclear export selinexor, the SYK inhibitor entospletinib, the dual SYK/JAK inhibitor certulatinib and the CDK inhibitors flavopiridol and dinaciclib.
- || everolimus / Generic mfg.
Clinical, Journal, Combination therapy: PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. (Pubmed Central) - Sep 23, 2020
Our study revealed that PI3K pathway was activated in at least 14.9% in EGFR-TKI resistant patients. EGFR-TKIs plus everolimus showed limited antitumor activity in EGFR mutant NSCLC patients with PI3K pathway aberrations.
- || Xofigo (radium Ra-223 dichloride) / Bayer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer (clinicaltrials.gov) - Sep 22, 2020
P2, N=283, Active, not recruiting, Sponsor: Bayer
EGFR-TKIs plus everolimus showed limited antitumor activity in EGFR mutant NSCLC patients with PI3K pathway aberrations. Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2020 --> Dec 2020
- | everolimus / Generic mfg.
Journal: Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes. (Pubmed Central) - Sep 21, 2020
We critically reviewed available data supporting the use of somatostatin analogs, chemotherapy, and target therapies (everolimus and sunitinib) in advanced lung NETs. In the review, ongoing trials in lung NETs and future developments in this research field are also discussed.
- || everolimus / Generic mfg., sirolimus / Generic mfg.
Clinical, Journal: Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients. (Pubmed Central) - Sep 21, 2020
Conclusions Because pre-defined limits of clinical relevance were not met, this DBS sampling method for sirolimus and everolimus cannot replace WB sampling in our center at this time. However, if the clinical setting is compatible with less strict limits for clinical relevance, this DBS method is suitable for clinical application.
- | tacrolimus / Generic mfg., everolimus / Generic mfg.
Journal: Early switch from tacrolimus to everolimus after liver transplantation: outcomes at two years. (Pubmed Central) - Sep 21, 2020
A CNI-free everolimus-based maintenance regimen appears feasible in approximately half of liver transplant patients. It preserves renal function effectively with good efficacy, without compromising safety or hematological tolerance.
- || simvastatin / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
Clinical, P2 data, Journal: A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex. (Pubmed Central) - Sep 21, 2020
The combination of simvastatin with mTORi in LAM patients is safe and well-tolerated from an adverse events perspective. The addition of simvastatin, however, was associated with decline in FEV1 and the efficacy of this combination should be explored in larger trials.
- || everolimus / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib-everolimus maybe... (Twitter) - Sep 19, 2020